1. Tricyclic Diterpenoids Selectively Suppress Androgen Receptor-Positive Prostate Cancer Cells.
- Author
-
Sekhon, Inderpal, Chen, Guanglin, Piri, Keyara, Shinkawa, Seiji, Ashong, Dennis, Zhang, Qiang, Wang, Guangdi, and Chen, Qiao-Hong
- Subjects
DITERPENES ,PROSTATE cancer ,CASTRATION-resistant prostate cancer ,CANCER cells ,LIGAND binding (Biochemistry) ,ABIRATERONE acetate - Abstract
Androgen receptor (AR) is a viable therapeutic target for lethal castration-resistant prostate cancer (CRPC), because the continued progression of CRPC is mainly driven by the reactivation of AR transcriptional activity. The current FDA-approved AR antagonists binding to ligand binding domain (LBD) become ineffective in CRPC with AR gene amplification, LBD mutation, and the evolution of LBD-truncated AR splice variants. Encouraged by the fact that tricyclic aromatic diterpenoid QW07 has recently been established as a potential N-terminal AR antagonist, this study aims to explore the structure–activity relationship of tricyclic diterpenoids and their potential to suppress AR-positive cell proliferation. Dehydroabietylamine, abietic acid, dehydroabietic acid, and their derivatives were selected, since they have a similar core structure as QW07. Twenty diterpenoids were prepared for the evaluation of their antiproliferative potency on AR-positive prostate cancer cell models (LNCaP and 22Rv1) using AR-null cell models (PC-3 and DU145) as comparisons. Our data indicated that six tricyclic diterpenoids possess greater potency than enzalutamide (FDA-approved AR antagonist) towards LNCaP and 22Rv1 AR-positive cells, and four diterpenoids are more potent than enzalutamide against 22Rv1 AR-positive cells. The optimal derivative possesses greater potency (IC
50 = 0.27 µM) and selectivity than QW07 towards AR-positive 22Rv1 cells. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF